Glabellar dynamics decoded to refine precision in botulinum toxin treatment
Journal of Cosmetic Dermatology · 2024-09 · 23 (9) · 2816-2820
DOI: 10.1111/jocd.16340 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 20.04.2024. Verfasst von Jovian Wan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Asia Pacific Aesthetic Academy, Hong Kong, China. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Forehead, Neuromuscular Agents, Skin Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glabellar lines (GL), located between the eyebrows, result from the activity of three muscles: the corrugator supercilii (CSM), procerus, and depressor supercilii muscles, collectively contributing to the appearance of aging.1, 2 Among these, the primary contributor is the CSM. Moreover, the upper medial fibers of the orbicularis oculi, known as the depressor supercilii, are intricately associated with both the CSM and procerus muscles.3 As aging progresses, these GL become more prominent, contributing to the portrayal of a persistent negative emotional state.4, 5 Recent research also indicates an increase in the muscular activity of the CSM with advancing age.6 The application of botulinum neurotoxin (BoNT) to induce chemical denervation, resulting in sustained yet reversible muscle relaxation, has emerged as the preferred cosmetic intervention for treatment of glabella region.3, 7 This area has been extensively explored within the literature, highlighting its importance.3, 8-10 Existing injection protocols employed to address the glabella predominantly involve a 5- or 7-point technique,11-17 specifically targeting the procerus, as well as the medial and lateral aspects of the CSM muscles (Figure 1).18 When administering toxin in the proximity of the glabellar region, migration through the orbital septum can lead to the weakening of the levator palpebrae superioris. Blepharoptosis, a complication frequently observed with toxin injection near the supraorbital margin in the mid-pupillary line or with higher toxin quantities, may manifest within 7–10 days post-injection and can persist for 2–4 weeks or even longer. The incidence of blepharoptosis varies among treatment groups in clinical trials, and notably, it is absent in placebo groups, underscoring its direct association with BoNT injection.19 A multicentre study conducted by Allergan for the United States Food and Drug Administration revealed a 5.4% incidence of blepharoptosis induced by BoNT type A among less-experienced injectors, contrasting with less than 1% among those with more experience. Reviewing 35 articles covering over 8000 patients, Cavallini et al.20 concluded that the rate of blepharoptosis is approximately 2.5%. Over the years, the incidence appears to have diminished, possibly due to injectors gaining enhanced expertise in administering BoNT type A. Notably, there is a scarcity of comprehensive documentation on this specific adverse event in the form of both case reports and case series. Despite the condition resolving spontaneously, patients commonly report substantial aesthetic and visual discomfort, making the waiting period for resolution particularly challenging.19 A compelling study conducted by De Almeida et al.21 aimed to validate the existence of glabellar contraction patterns and assess changes following repeated BoNT treatments. The researchers evaluated photographs of adult volunteers, identifying five distinct glabellar contraction patterns: "U," "V," "convergent arrows," "omega," and "inverted omega." The study included 334 individuals, predominantly women (86.2%) and men (13.8%), with 36 individuals having received prior treatments. The findings demonstrated the reappearance of each individual's original contraction pattern following the dissipation of the toxin's effects. The researchers highlighted the importance of tailoring treatment approaches based on the specific observed contraction pattern, including adjustments in injection sites and doses of BoNT. This study emphasizes the critical consideration of individual differences in facial animation and contraction patterns for precise and natural outcomes when administering BoNT. This study aims to integrate insights from pertinent literature and formulate an improved injection protocol for the safe and effective administration of BoNT for treating GL. This protocol is established based on an innovative understanding of glabellar contraction patterns. The CSM, arising from the superomedial region of the bony orbital rim, follows a superolateral trajectory at an angle of approximately 30°, extending to the midpoint of the eyebrow, where it attaches to the dermal layer of the skin. Positioned beneath the frontalis muscle, the CSM originates from the frontal bone, specifically around 16 mm above the horizontal intercanthal plane, within a range of 4–14 mm from the midline. Its insertion occurs in the dermal layer, positioned 30 mm above the horizontal intercanthal plane and 16–35 mm from the midline, demonstrating a distinct interconnection with the frontalis muscle.22 In the context of Asian individuals, the vertical dimension of the CSM is comparatively shorter at 15 mm compared to the 21 mm observed in Caucasians. Structurally, the CSM comprises two distinct muscle bellies: oblique and transverse. The oblique belly follows a vertical trajectory, while the transverse belly exhibits a horizontal orientation.22 Specifically, the oblique belly manifests in two forms: narrow and broad.3 The narrow variation appears as a slender rectangular structure,22 seamlessly integrating with the frontalis muscle in the medial section of the transverse belly. Conversely, the broad type adopts a triangular configuration, covering a substantial portion of the transverse belly's surface. The broad oblique belly tends to generate more robust muscle contractions in the eyebrow region above the mid-pupillary line. It is noteworthy that distinguishing between these two types of CSM muscles can be challenging, and the injection points for both types remain identical. The primary function of the CSM involves pulling the eyebrows downward and inward, resulting in the formation of vertical lines during a frowning expression.23 Paralysis of the CSM leads to the elimination of glabellar lines and an expansion of the eyebrows. We identify two primary contraction patterns in the glabella: the oblique line pattern and the vertical line pattern (Figure 2). The oblique line pattern is characterized by lines traversing the glabella region at an angle, resulting in a diagonal aesthetic pattern induced by the contraction of the oblique belly of the CSM (Figure 3A). In contrast, the vertical line pattern entails the development of predominantly vertically oriented lines or wrinkles (Figure 3B), arising from the contraction of the transverse belly of the CSM. The glabellar muscles demonstrate anatomical interconnectedness rather than distinct isolation.22 Consequently, the administration of BoNT into the CSM may result in diffusion to adjacent muscles (Figure 4). To ensure precise administration of BoNT injections for GL, targeting specific anatomical points is essential. The medial and lateral points serve as key landmarks for injection placement. The medial point, located at the interciliary point on the frontal notch, is palpable and identifiable. In contrast, the lateral point is found at the junction of the mid-pupillary line and superciliary arch. To optimize injection accuracy, injections should be administered at four specific points, namely the medial and lateral points. When addressing oblique GL, injections at the medial point should be directed to a middle depth, while injections for vertical GL should penetrate deeper. Conversely, injections at the lateral point should be superficial (subdermal) to target both oblique and transverse muscle fibers. For precise injection technique at the medial point for oblique GL, the needle should be inserted deeply until it contacts the periosteum before injecting. However, for vertical GL, after reaching the periosteal layer, the needle should be withdrawn 2–3 mm before gradually administering BoNT into the muscle.24 Subdermal injection is preferred for the lateral points, with caution applied to the frontal notch during injection to prevent inadvertent entry of BoNT into the orbital cavity.25 Additionally, orienting the injection needle upwards is recommended to facilitate accurate administration (Figure 5). The aim of this study was to develop an enhanced injection protocol for the safe and effective administration of BoNT for treating GL. Central to this technique is an understanding of the glabellar contraction pattern, whether it presents as oblique or vertical lines, determined by the muscle bellies of the CSM.22 The CSM, composed of oblique and transverse bellies, forms the focal point of this injection protocol. By carefully observing the glabellar contraction pattern and comprehending the underlying anatomy, a more accurate approach to injections can be achieved, thereby reducing the risk of blepharoptosis following BoNT treatment. Clinical experience underscores that variations in dosage, injection sites, direction of the needle, hand position, and the number of injection sites can influence the final outcomes and treatment duration.3 Recognizing these subtleties is crucial as they significantly influence patient satisfaction and can affect the confidence of the treating physician during the procedure.26 Therefore, careful attention should be given to these considerations. This clinical commentary introduces a novel technique for administering BoNT injections targeting GL. It is important to note that this commentary is not based on experimental data but rather on our extensive clinical experience. The technique outlined here reflects our established approach, honed over years of practical application and patient care. While we recognize the significance of empirical evidence in validating new methodologies, we believe that sharing insights from our real-world clinical experience can contribute valuable perspectives to the field. Thus, this commentary serves as a platform to discuss and disseminate our observations and techniques, offering clinicians an additional perspective to consider in their practice. We welcome further discussion and collaboration to advance the understanding and refinement of BoNT injection techniques for GL treatment. The origins of glabellar contraction patterns have not been intentionally created; rather, they have been identified and confirmed over time through informal communications among colleagues.21 In the study conducted by De Almeida et al.,21 five glabellar contraction patterns were delineated, with the most frequently encountered being the "U" and "V" patterns. The "U" pattern involves the approximation and depression of the space between the eyebrows during glabellar contraction, exhibiting variable intensity but limited range, resulting in a movement resembling the letter "U." Conversely, the "V" pattern encompasses a wider range of approximation and depression of the glabella, occurring with higher intensity compared to the "U" group. At rest, patients with the "U" pattern exhibit arched eyebrows, while those with the "V" pattern showcase more horizontal and lowered eyebrows. To simplify our approach, we propose categorizing glabellar contractions into two groups: oblique lines and vertical lines. To avoid unfavorable outcomes, the injection site plays a crucial role in preventing ptosis, emphasizing the necessity for it to be as superior as possible to the edge of the orbital rim.3 The origin point of the CSM is situated immediately above the upper inner edge of the orbital rim. Considering that one unit of BoNT is noted to disperse within a range of 1.5 to 3 cm, it is permissible to administer injections slightly above the origin site of the CSM.27, 28 In conclusion, the information provided regarding the dimensions and positioning of the CSM should be considered when administering BoNT injections to treat GL. All authors have reviewed and approved the article for submission. Conceptualization, Kyu-Ho Yi, Jovian Wan, Raymond Wu. Writing—Original Draft Preparation, Kyu-Ho Yi, Raymond Wu. Writing—Review & Editing, Kyu-Ho Yi, Jovian Wan. Visualization, Kyu-Ho Yi. Supervision, Hee-Jin Kim. This study was conducted in compliance with the Declaration of Helsinki. Consent was received from the families of the deceased patients before beginning the dissection. The authors sincerely thank those who donated their bodies to science for anatomical research. The results of such research can aid in mankind's overall knowledge, which can improve patient care. Therefore, these donors and their families deserve the greatest gratitude. The authors have all considered the conflict of interest statement included in "Author Guidelines." To the best of our knowledge, no aspect of the authors' current personal or professional life might significantly affect the views presented on this manuscript. The authors declare no conflicts of interest. This study was conducted in compliance with the Declaration of Helsinki. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asia Pacific Aesthetic Academy, Hong Kong, China.
- Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, Seoul, Korea.
- Maylin Clinic (Apgujeong), Seoul, Korea.
ORCID-Profile: Hee-Jin Kim, Kyu-Ho Yi
Zitieren
APA
Wan, J., Wu, R., Kim, H. J., & Yi, K. H. (2024). Glabellar dynamics decoded to refine precision in botulinum toxin treatment. Journal of Cosmetic Dermatology, 23(9), 2816-2820. https://doi.org/10.1111/jocd.16340
Vancouver
Wan J, Wu R, Kim HJ, Yi KH. Glabellar dynamics decoded to refine precision in botulinum toxin treatment. Journal of Cosmetic Dermatology. 2024;23(9):2816-2820. doi:10.1111/jocd.16340
BibTeX
@article{Wan2024,
author = {Wan, Jovian and Wu, Raymond and Kim, Hee-Jin and Yi, Kyu-Ho},
title = {Glabellar dynamics decoded to refine precision in botulinum toxin treatment},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
volume = {23},
number = {9},
pages = {2816--2820},
doi = {10.1111/jocd.16340}
}
EUVIMED